Engineering and design software provider PTC (NASDAQ:PTC) will be reporting earnings tomorrow afternoon. Here’s what to ...

Citi lowered the firm’s price target on PTC (PTC) to $195 from $200 and keeps a Neutral rating on the shares ahead of the earnings report. The ...

Inc., a leading provider of software solutions for product design, manufacturing, and service, continues to navigate a challenging macroeconomic environment while positioning itself for future growth.

PTC PTC underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Get a deeper insight into the potential performance of PTC Inc. (PTC) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...

A handwritten note discovered near his body suggested that financial hardship was a significant factor behind his tragic ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

The case gained prominence after PTC News highlighted it, which led the child’s family members—his grandparents and uncle—to ...

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

Barclays analyst Saket Kalia maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $215.00. The company’s ...

The stock's fall snapped a two-day winning streak.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...